Study of Subcutaneous Continuous Administration of Levodopa/Carbidopa Solution (ND0612) in Healthy Volunteers
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
It will be a single dose, single-center, randomized, double-blind, placebo-controlled dose
escalation study of SC continuously-delivered LD/CD solution (ND-0612) for 24 hours in
healthy volunteers.
Objectives are to determine:
1. the maximal tolerated dose of SC ND-0612
2. the steady state plasma concentration of LD and CD following SC ND-0612 administration.
Each treatment group will include 6 healthy volunteers. Dosing will be done in a sequential
manner.